Literature DB >> 22740911

Single nucleotide polymorphisms in DNA repair genes and risk of cervical cancer: A case-control study.

Lihua Zhang1, Zhenchao Ruan, Qingya Hong, Xiangzhen Gong, Zhengguang Hu, Yan Huang, Aidi Xu.   

Abstract

In this report, we describe a case control study in a Chinese population aimed at identifying possible associations between susceptibility to cervical cancer and single nucleotide polymorphisms in XRCC1 194C>T, XRCC1 280G>A, XRCC1 399G>A, ERCC2 751A>C, ERCC2 156C>A, ERCC1 118C>T, PARP1 762T>C, RAD51 135G>C and HER2 655A>G. The cases comprised 154 patients: 80 cervical squamous cell carcinomas (SCCs), 2 adenocarcinomas and 72 cervical intraepithelial neoplasias (CINs). A total of 177 healthy women were recruited as the controls. A significant association was found between ERCC1 118C>T and SCC in the additive genetic model [odds ratio (OR)=1.711; 95% confidence interval (CI), 1.089-2.880; p=0.021] and the dominant genetic model (OR=1.947; 95% CI, 1.056-3.590; p=0.033). Among women with a smoking family member, ERCC1 118C>T increased SCC risk in the additive model (OR=2.800; 95% CI, 1.314-5.968; p=0.008). For women who had first intercourse before 22 years of age, XRCC1 280G>A was found to act as a protective factor for SCC under the additive model (OR=0.228; 95% CI, 0.058-0.900; p=0.035), while RAD51 135G>C was a risk factor for CIN (OR=4.246; 95% CI, 1.335-13.502; p=0.014). For women who had first intercourse after 22 years of age, the additive genetic model showed RAD51 135G>C (OR=0.359; 95% CI, 0.138-0.934; p=0.036) and HER2 655A>G (OR=0.309; 95% CI, 0.098-0.972; p=0.045) to be protective factors for SCC. XRCC1 399G>A increased CIN risk among women who first gave birth before the age of 22 in the additive genetic model (OR=4.459; 95% CI, 1.139-17.453; p=0.032). For those who first gave birth after age 22, ERCC1 118C>T was found to be a risk factor for SCC in the additive genetic model (OR=1.884; 95% CI, 1.088-3.264; p=0.024). A significant interaction was observed between RAD51 135G>C and age at first intercourse (p(interaction)=0.033 for SCC, p(interaction)=0.021 for CIN), as well with sexual partner number (p(interaction)=0.001 for SCC). The interaction between HER2 655A>G and age at first intercourse, ERCC2 156C>A and family smoking status and XRCC1 280G>A and alcohol consumption were significant, with p(interaction)=0.023 for SCC, p(interaction)=0.021 for CIN and p(interaction)=0.025 for SCC, respectively.

Entities:  

Year:  2011        PMID: 22740911      PMCID: PMC3362506          DOI: 10.3892/ol.2011.463

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  41 in total

1.  Genetic model testing and statistical power in population-based association studies of quantitative traits.

Authors:  Guillaume Lettre; Christoph Lange; Joel N Hirschhorn
Journal:  Genet Epidemiol       Date:  2007-05       Impact factor: 2.135

2.  Lifetime cigarette smoke and second-hand smoke and cervical intraepithelial neoplasm--a community-based case-control study.

Authors:  Hsiu-Ting Tsai; Ying-Mei Tsai; Sheau-Fang Yang; Kuen-Yuh Wu; Hung-Yi Chuang; Trong-Neng Wu; Chi-Kung Ho; Cheng-Chieh Lin; Ying-Se Kuo; Ming-Tsang Wu
Journal:  Gynecol Oncol       Date:  2007-01-03       Impact factor: 5.482

3.  Reaction mechanism of human DNA repair excision nuclease.

Authors:  D Mu; D S Hsu; A Sancar
Journal:  J Biol Chem       Date:  1996-04-05       Impact factor: 5.157

4.  Reconstitution of human DNA repair excision nuclease in a highly defined system.

Authors:  D Mu; C H Park; T Matsunaga; D S Hsu; J T Reardon; A Sancar
Journal:  J Biol Chem       Date:  1995-02-10       Impact factor: 5.157

5.  Polymorphisms of the DNA repair gene XRCC1 and risk of gastric cancer in a Chinese population.

Authors:  H Shen; Y Xu; Y Qian; R Yu; Y Qin; L Zhou; X Wang; M R Spitz; Q Wei
Journal:  Int J Cancer       Date:  2000-11-15       Impact factor: 7.396

6.  ERCC1 gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy.

Authors:  David J Park; Wu Zhang; Jan Stoehlmacher; Denice Tsao-Wei; Susan Groshen; Ji Gil; Jim Yun; Erin Sones; Nalin Mallik; Heinz-Josef Lenz
Journal:  Clin Adv Hematol Oncol       Date:  2003-03

7.  Selected base excision repair gene polymorphisms and susceptibility to biliary tract cancer and biliary stones: a population-based case-control study in China.

Authors:  Wen-Yi Huang; Yu-Tang Gao; Asif Rashid; Lori C Sakoda; Jie Deng; Ming-Chang Shen; Bin-Sheng Wang; Tian-Quan Han; Bai-He Zhang; Bingshu E Chen; Philip S Rosenberg; Stephen J Chanock; Ann W Hsing
Journal:  Carcinogenesis       Date:  2007-11-04       Impact factor: 4.944

Review 8.  Viruses in human cancers.

Authors:  H zur Hausen
Journal:  Science       Date:  1991-11-22       Impact factor: 47.728

9.  Epidemiology and prevention of human papillomavirus and cervical cancer in China and Mongolia.

Authors:  Ju-Fang Shi; You-Lin Qiao; Jennifer S Smith; Bolormaa Dondog; Yan-Ping Bao; Min Dai; Gary M Clifford; Silvia Franceschi
Journal:  Vaccine       Date:  2008-08-19       Impact factor: 3.641

10.  BRCA2 BRC motifs bind RAD51-DNA filaments.

Authors:  Vitold E Galkin; Fumiko Esashi; Xiong Yu; Shixin Yang; Stephen C West; Edward H Egelman
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-03       Impact factor: 11.205

View more
  16 in total

1.  Genetic 135G/C polymorphism of RAD51 gene and risk of cancer: a meta-analysis of 28,956 cases and 28,372 controls.

Authors:  Bei-Bei Zhang; Dao-Gang Wang; Chao Xuan; Gui-Li Sun; Kai-Feng Deng
Journal:  Fam Cancer       Date:  2014-12       Impact factor: 2.375

2.  Decreased expression of DNA repair genes (XRCC1, ERCC1, ERCC2, and ERCC4) in squamous intraepithelial lesion and invasive squamous cell carcinoma of the cervix.

Authors:  Deepti Bajpai; Ayan Banerjee; Sujata Pathak; Sunesh K Jain; Neeta Singh
Journal:  Mol Cell Biochem       Date:  2013-02-23       Impact factor: 3.396

3.  XRCC1 polymorphisms and cervical cancer risk: an updated meta-analysis.

Authors:  Jie Mei; Hai-Xia Duan; Ling-Ling Wang; Sen Yang; Jie-Qiang Lu; Ting-Yan Shi; Yu Zhao
Journal:  Tumour Biol       Date:  2013-09-21

4.  PARP1 rs1136410 Val762Ala contributes to an increased risk of overall cancer in the East Asian population: a meta-analysis.

Authors:  Yijuan Xin; Liu Yang; Mingquan Su; Xiaoli Cheng; Lin Zhu; Jiayun Liu
Journal:  J Int Med Res       Date:  2021-03       Impact factor: 1.671

Review 5.  A review on the genetic polymorphisms and susceptibility of cancer patients in Bangladesh.

Authors:  Golap Babu; Shad Bin Islam; Md Asaduzzaman Khan
Journal:  Mol Biol Rep       Date:  2022-03-11       Impact factor: 2.742

6.  Association between the PARP1 Val762Ala polymorphism and cancer risk: evidence from 43 studies.

Authors:  Rui-Xi Hua; He-Ping Li; Yan-Bing Liang; Jin-Hong Zhu; Bing Zhang; Sheng Ye; Qiang-Sheng Dai; Shi-Qiu Xiong; Yong Gu; Xiang-Zhou Sun
Journal:  PLoS One       Date:  2014-01-28       Impact factor: 3.240

7.  PARP-1 Val762Ala polymorphism and risk of cancer: a meta-analysis based on 39 case-control studies.

Authors:  Qin Qin; Jing Lu; Hongcheng Zhu; Liping Xu; Hongyan Cheng; Liangliang Zhan; Xi Yang; Chi Zhang; Xinchen Sun
Journal:  PLoS One       Date:  2014-05-22       Impact factor: 3.240

8.  Meta-analysis of XRCC1 polymorphism and risk of female reproductive system cancer.

Authors:  Na-Na Yang; Ying-Fan Huang; Jian Sun; Ying Chen; Zhong-Min Tang; Jin-Fang Jiang
Journal:  Oncotarget       Date:  2017-04-25

9.  Association between XRCC1 polymorphisms and the risk of cervical cancer: a meta-analysis based on 4895 subjects.

Authors:  Xianling Zeng; Yafei Zhang; Ting Yue; Taohong Zhang; Junxia Wang; Yan Xue; Ruifang An
Journal:  Oncotarget       Date:  2017-01-10

10.  Relationship between Rad51 G135C and G172T variants and the susceptibility to cancer: a meta-analysis involving 54 case-control studies.

Authors:  Mengmeng Zhao; Pin Chen; Yanbin Dong; Xianji Zhu; Xilong Zhang
Journal:  PLoS One       Date:  2014-01-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.